Premium
I.V. Administration of L‐G N RH‐PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice
Author(s) -
BenYehudah Ahmi,
Prus Diana,
LorberboumGalski Haya
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(200102)9999:9999<::aid-ijc1185>3.0.co;2-e
Subject(s) - adenocarcinoma , in vivo , medicine , ratón , cancer research , in vitro , nude mouse , colorectal cancer , fusion protein , growth inhibition , cancer , biology , gene , biochemistry , microbiology and biotechnology , recombinant dna
When developing new anti‐cancer therapeutic treatments, it is crucial to find the correct route of administration and timetable for treatment. Recently, we constructed the L‐GnRH‐PE66 chimeric protein, which can target and kill adenocarcinoma cells both in vitro and in vivo . We examined the ability of the L‐GnRH‐PE66 chimeric protein to inhibit tumor growth in colon carcinoma xenografted nude mice, using different routes of administration and various timetables of treatment. In addition, we examined the ability of the chimeric protein to inhibit tumor growth of large tumors that resemble those encountered in human patients in the clinical setting. We found that an i.v. dose of 12.5 μg given every 48 hr was the most efficacious in inhibiting tumor growth. Tumors treated with this concentration of the chimeric protein were 4.4 times smaller in volume and 3.4 times smaller in weight than those in the control groups. This protocol of L‐GnRH‐PE66 treatment is an improvement on our previously suggested treatment for adenocarcinoma in humans. An i.v. injection every 48 hr is effective, less toxic and less painful. Our results further support the use of L‐GnRH‐PE66 as an effective treatment for adenocarcinoma in humans. © 2001 Wiley‐Liss, Inc.